In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Potential Implications: The peptides ability to expedite the healing of incisional skin wounds opens up possibilities for therapeutic applications in wound management and recovery
THIRD-PARTY TESTED QUALITY: Each batch of Meraki methylene blue USP grade is third-party tested for purity and identity to support consistent quality, careful formulation, and dependable bottle-to-bottle standards
Tendon, Ligament, and Connective Tissue Due to limited blood supply, tendons and ligaments present significant challenges in repair research